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Abstract
Background and aims: The aim of the present investigation was to examine the anti-wasting effects of
theophylline (a methylxantine present in tea leaves) on a rat model of cancer cachexia.
Methods: The in vitro effects of the nutraceuticals on proteolysis were examined on muscle cell cultures submitted
to hyperthermia. Individual muscle weights, muscle gene expression, body composition and cardiac function were
measured in rats bearing the Yoshida AH-130 ascites hepatoma, following theophylline treatment.
Results: Theophylline treatment inhibited proteolysis in C2C12 cell line and resulted in an anti-proteolytic effect on
muscle tissue (soleus and heart), which was associated with a decrease in circulating TNF-alpha levels and with a
decreased proteolytic systems gene expression. Treatment with the nutraceutical also resulted in an improvement
in body composition and cardiac function.
Conclusion: Theophylline - alone or in combination with drugs - may be a candidate molecule for the treatment
of cancer cachexia.
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Background
The development of cancer cachexia is the most common
manifestation of advanced malignant disease. Indeed,
cachexia occurs in the majority of terminally ill cancer
patients, and it is responsible for the death of 22% of can-
cer patients [1]. The abnormalities associated with cancer
cachexia include anorexia, weight loss, muscle loss and at-
rophy, anaemia and alterations in carbohydrate, lipid and
protein metabolism [2]. Some of these effects are asso-
ciated also with anti-tumour treatment. The degree of
cachexia is inversely correlated with the survival time of
the patient and it always implies a poor prognosis [3].
Perhaps one of the most relevant characteristics of cach-
exia is that of asthenia, which reflects the important
muscle wasting that takes place in the cachectic cancer
patient [4]. Lean body mass depletion is one of the main
trends of cachexia and it involves not only skeletal muscle
but it also affects cardiac proteins, resulting in important
alterations in heart performance. In addition to the
increased muscle protein degradation found during can-
cer growth, the presence of the tumour also induces an
increased rate of DNA fragmentation in skeletal muscle
in both rats and mice [5].
One of the factors contributing to wasting during can-
cer is muscle loss through the activation of proteolysis
[6]. The precise mechanism by which intracellular pro-
teins are degraded is not fully understood, although it is
accepted that proteolysis may occur inside and outside
the lysosomes. The ATP-ubiquitin-dependent proteolytic
system has been shown to be involved in the alterations
of protein metabolism related to several pathophysio-
logical conditions such as cancer, chronic infection and
chronic heart failure [7]. During these pathological con-
ditions commented on, muscle wasting leads to cachexia,
a syndrome characterized by weight loss and profound
metabolic abnormalities. Unfortunately therapeutic ap-
proaches to stop muscle wasting have not been very
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satisfactory, partly because of the toxicity of inhibitors of
the ubiquitin-dependent proteolytic system.
Theophylline (1,3-dimethylxanthine) is an alkaloid that
belongs to the same family as caffeine and theobromine
[8]. It is present in tealeaves and chocolate and its main
effects seem related with relaxation of bronchial muscles
together with peripheral blood vessel dilatation [9]. It is
for this reason that the alkaloid has been used in the
treatment of asthma and patients with chronic obstructive
pulmonary disease (COPD) [10,11]. In addition, theophyl-
line decreases circulating TNF-α and increases plasma IL-
10, an anti-inflammatory cytokine [12]. Additionally,
theophylline is able to increase both the expression and
the amount of the gene PPAR-γ, therefore suggesting an
additional anti-inflammatory potential [13].
Taking into consideration its anti-inflammatory prop-
erties, theophylline could be a good candidate for the
treatment of muscle wasting. Bearing this in mind, we
have investigated the effects of theophylline treatment
both in vitro, in an hyperthermia model which we previ-
ously reported as a suitable model for studying the anti-
proteolytic potential of drugs used in the treatment of
muscle wasting [14], and in vivo, in rats bearing the
Yoshida AH-130 ascites hepatoma, a tumour which
induces a high degree of muscle wasting associated with
cachexia.
Methods
Cell culture
C2C12 mouse skeletal muscle cells were obtained from
the American Type Culture Collection. Cells were pas-
saged in high-glucose Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal bovine
serum (FBS), 100 U/mL penicillin, 100 μg/mL strepto-
mycin, 25 ng/ml fungizone, 110 μg/mL sodium pyruvate,
and 2 mM L-glutamine, in a humidified atmosphere of
5% CO2 and 95% air at 37°C. For experimental analyses,
cells were seeded at 3.7 × 104 cells/cm2 in 10% FBS/
DMEM until they reached 90–100% confluence 24 h
later. At this time, the medium was replaced by DMEM
containing 10% horse serum (HS) for induction of differ-
entiation for genetically modified cells. Abundant myo-
tube formation, monitored microscopically, occurred
after 4 days in 10% horse serum HS/DMEM. Such fused
myotube cultures were utilized for experimental analysis
5 days after transferring the cells to 10% HS/DMEM.
Hyperthermia model and measurement of protein
degradation
C2C12 myotubes were pre-labelled with L-[2,6-3H]
phenylalanine (Amersham, Bucks, UK) as described [15]
for a 24 h period, after which they were washed exten-
sively in PBS, and incubated in fresh DMEM for a 2 h
period at 37°C, until no more radioactivity appeared in
the medium. Protein degradation was measured by
the release of [2,6-3H]phenylalanine into the medium
(DMEM-supplemented with 1% glutamine, 1% penicillin-
streptomycin-fungizone and 10%HS) after 6 h incubation
at 37 or 41°C according to Gulve et al [16]. After the in-
cubation, the cells were rinsed twice in PBS. Cultures
were incubated with or without different concentrations
of theophylline (0.01 and 0.1 mM) [17,18]. The hyper-
thermia method to induce protein degradation has been
previously described by Smith et al. [19].
Animals
Male Wistar rats (Harlan, Barcelona, Spain) of 5 weeks
(initial body weight = 154 g) of age were used in the differ-
ent experiments. The animals were maintained at 22± 2°C
with a regular light–dark cycle (light on from 08:00 a.m.
to 08:00 p.m.) and had free access to food and water. The
food intake was measured daily. All animal manipulations
were made in accordance with the European Community
guidelines for the use of laboratory animals. Ethical ap-
proval was obtained from both the University of Barcelona
and the Generalitat de Catalunya Ethics Comittees.
Tumour inoculation and treatment
Rats were divided into 2 groups namely control and
tumour hosts. The tumour rats received an intraperitoneal
inoculum of 108 AH-130 Yoshida ascites hepatoma cells
obtained from tumours that were in exponential phase of
growth as previously described by our group [6,20]. The
tumour group was divided into treated and untreated, the
former being administered a daily intragastric (i.g.) dose of
theophylline (50 mg/kg body weight (bw), dissolved in
corn oil) [9] and the latter a corresponding volume of
solvent (corn oil). On day 7 after tumour transplantation,
the animals, showing a high degree of cachexia accompan-
ied by a marked weight loss [21], were weighed and anaes-
thetized with an i.p. injection of ketamine/xylazine
mixture (3:1) (ImalgeneW and RompunW respectively).
The tumour was harvested from the peritoneal cavity and
its volume and number of cells evaluated. Tissues were
rapidly excised, weighted, and frozen in liquid nitrogen.
Body composition analysis
A nuclear magnetic resonance spectroscopy device
(EchoMRI-700™, Echo Medical Systems, Houston, TX)
was used to assess body composition with a sensitivity of
2 g. Fat, muscle, and tissue-free body fluids generate dif-
ferent signals in response to various radio frequency
pulses at distinct static magnetic fields [22]. A series of
radio pulses at 2 MHz induce changes in magnetic
polarization of hydrogen nuclei. These changes decay, or
“relax”, with different relaxation times in different sub-
stances (www.echomri.com). The analyser is sensitive to
NMR relaxation times in a range containing those of fat,
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lean, and saline, and so it detects and differentiates their
amounts. In this study, body composition was analysed
one day before starting the treatment and one day before
sacrifice (7 days), and the results are expressed as the
difference between both measurements [23].
Echocardiographic study
Rats were anesthetized using 1.5% isoflurane and laid in
supine position on a platform with all legs taped to ECG
electrodes for heart rate monitoring. Body temperature
was monitored and maintained at 36–38°C using a heat-
ing pad. All hair was removed from the chest. A high
resolution echocardiography system (Vevo 770; Visual-
Sonics Inc, Toronto, Canada) was used. The following
parameters were assessed using M-mode and: the thick-
ness of intraventricular septum (IVS), Left ventricle
diameter (LVD), posterior wall thickness (PWT). The LV
end-diastolic volume (LV Vol dia) and end-systolic vol-
ume (LV Vol sys) were traced and calculated in B-mode
to account for altered ventricular geometry [23]. In this
study, echocardiography was performed one day before
starting the treatment (results not shown) and one day
before sacrifice (7 days).
RNA isolation
Total RNA from heart and soleus muscle was extracted
by TriPureTM kit (Roche, Barcelona, Spain), a commer-
cial modification of the acid guanidinium isothiocyanate/
phenol/ chloroform method [24].
Real-time PCR (polymerase chain reaction)
First-strand cDNA was synthesized from total RNA with
oligo dT15 primers and random primers pdN6 by using a
cDNA synthesis kit (Transcriptor Reverse Transcriptase,
Roche, Barcelona, Spain). Analysis of mRNA levels for the
genes from the different proteolytic systems was per-
formed with primers designed to detect the following
gene products: ubiquitin (Forward 50 GATCCAGGA
CAAGGAGGGC 30, Reverse 50 CATCTTCCAGCTGCT
TGCCT30); E2 (Forward 50 AGGCGAAGATGGCGGT 30;
Reverse 50 TCATGCCTGTCCACCTTGTA 30); C2
(Forward 50 GTTTCCATTGGGATTGTTGG 30; Reverse
50 TGTTCCATTGGTTCATCAGC 30); C8 proteasome
subunit (Forward 50 CAACCATGACAACCTTCGTG 30;
Reverse 50 GCCTCAAGC CTTCTCTT TG 30); MuRF-1
(Forward 50 ATCACTCAGGAGCAGGAGGA 30; Reverse
50 CTT GGCACTCAAGAGGAAGG 30); Atrogin-1
(Forward 50 GTTTCCATTGGGATTGTTGG 30; Reverse
50 TGTTCCATTGGTTCATCAGC 30); m-calpain (For-
ward 50 TTGAGCTGCAGACCATC 30; Reverse 50
GCAGC TTGAAACCTGCTTCT 30) and cathepsin B
(Forward 50 CTGCTGAGGACCTGCTTAC 30; Reverse 50
CACAGGGAGGG ATGGTGTA 30); 18 S (Forward 50
CGCAGAATTCCCACTCCCGACCC 30; Reverse 50C
CCAAGCTCCAACTA CGAG C 30). To avoid the detec-
tion of possible contamination by genomic DNA, primers
were designed in different exons. The real-time PCR was
performed using a commercial kit (LightCycler TM Fas-
tStart DNA MasterPLUS SYBR Green I, Roche, Barcelona,
Spain). The relative amount of all mRNA was calculated
using comparative CT method. 18 S mRNA was used as
the invariant control for all studies.
Statistical analysis
Statistical analysis of the data was performed by means
of one-way and two-way analysis of variance (ANOVA)
(post-test Duncan).
Results and discussion
In order to test the proteolytic modulatory capacity of
theophylline (a nutraceutical present in tea), we chose
the model of hyperthermia [19]. Indeed, C2C12 cells
exposed to 41°C for 6 hours demonstrated a significant
increase in proteolytic rate, and theophylline was able to
significantly reduce the proteolysis during hyperthermia
(0.01 mM 9% and 0.1 mM 10%) (Figure 1).
Bearing in mind the results obtained in vitro, the next
aim of the present investigation was to see if this alkal-
oid was also able to influence muscle proteolysis in vivo.
We investigated the effects of theophylline treatment in
rats bearing the Yoshida AH-130 ascites hepatoma. We
have previously shown that the cachectic syndrome is
invariably associated with weight loss with skeletal
muscle waste in different experimental cancer models
[20,25] also observed in the present study (Figures 2 and
3). Theophylline treatment did not influence food intake
in the tumour bearing animals, neither did it influence
tumour growth (Figure 2). These results are in contrast
Figure 1 Effect of theophylline on the proteolytic rate of C2C12
cells under hyperthermia. Values for protein degradation are
presented as the percentage of the respective control value at 37°C
of the amino acid radioactivity in the medium versus the total
radioactivity incorporated into protein (for further details, see the
Material and Methods section). All data are means ± SEM. The
number inside the bars represents the concentration of theophylline
(mM). Values that are significantly different by one-way ANOVA
(post-test Duncan), from the control (non treated) group are
indicated by: # p< 0.05, ## p< 0.01. Values that are significantly
different by one-way ANOVA (post-test Duncan) from hyperthermia
are indicated by: *** p< 0.001.
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with previous studies demonstrating that theophylline
induces apoptosis and growth inhibition in tumour cells
in vitro [26]; also, in vivo treatment with theophylline of
mice implanted with melanoma cells results in a marked
decrease in hepatic and pulmonary metastases [27].
From the results depicted in Figure 2 it can be seen
that, in spite of the fact that theophylline treatment
resulted in a tendency for higher body weight, the dif-
ference did not reach statistical significance. However,
the treatment with this alkaloid resulted in a significant
increase in the weight of soleus (10%) and cardiac mus-
cles (11.5%), both of them with red and aerobic fibres
(Figure 3). Conversely, no effects of treatment were ob-
served with other muscles (non significant differences:
gastrocnemius T= 572 ± 13 (5) vs T+TPH=580 ± 12 (6);
EDL T=44 ± 1 (5) vs T+TPH=43.7 ± 1 (6); tibialis
T= 184 ± 6 (5) vs T +TPH=185 ± 6 (6)). These results
are in agreement with the body composition of the ani-
mals. Indeed, as shown in Table 1, a significant decrease
of fat and lean mass was observed due to the tumour
growth. The treatment with theophylline resulted in a
tendency for higher lean body mass, although the differ-
ence did not reach statistical significance. Interestingly,
however, the animals treated with theophylline lost sig-
nificantly less fat mass (Table 1). This observation is very
Figure 3 Effect of theophylline (50 mg/kg bw) on soleus and
heart weights in rats bearing the Yoshida AH-130 ascites
hepatoma. Results are mean± SEM. Muscles weights are expressed
as mg/100 g of initial body weight (IBW). C = non-tumour-bearing
rats, T = tumour-bearing rats, T + TPH= tumour-bearing rats treated
with theophylline. Values that are significantly different by two-way
analysis of variance (ANOVA) are indicated by: # p< 0.05, ## p< 0.01
(tumour effect); * p< 0.05 (treatment effect).
Figure 2 Effect of theophylline (50 mg/kg bw) on body weight
change, food intake and tumour content in rats bearing the
Yoshida AH-130 ascites hepatoma. Results are mean± SEM. Body
weight change is expressed as the difference between final body
weight and initial body weight (IBW). Food intake is expressed in
g/100 g IBW and refers to the food ingested during the period of
the experiment prior to sacrifice, which took place 7 days after
tumour inoculation. Tumour cell content is expressed in millions
of cells. C = non-tumour-bearing rats, T = tumour-bearing rats,
T + TPH= tumour-bearing rats treated with theophylline. Values that
are significantly different by two-way analysis of variance (ANOVA)
are indicated by: ### p< 0.001 (tumour effect).
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surprising since theophylline has been demonstrated to
be a lipolytic agent both in experimental animals [28]
and humans [29], its mechanism of action being based
on the inhibition of cAMP phosphodiesterase (PDE)
[30]. These data suggest that an abnormal regulation of
adipose tissue metabolism associated with tumour bur-
den exists. The inhibition of PDE could be the mechan-
ism underlying the effects of theophylline on muscle
tissue, in this case on an aerobic muscle, this idea has
been already suggested by others while studying muscle
protein catabolism in septic rats [31].
Muscle catabolism associated with cancer is influenced
by an activation of the ubiquitin-dependent proteolytic
system [6]. Bearing this in mind, we decided to investi-
gate the effects of theophylline on the gene expression
of the different proteolytic systems. The results, pre-
sented in Table 2, show an increased expression of some
genes involved in the ATP-ubiquitin-dependent proteo-
lytic pathway in heart (ubiquitin, C2, C8, E2, MuRF-1
and Atrogin-1) and soleus muscle (ubiquitin, E2,
Atrogin-1 and MuRF-1) of tumor-bearing animals in re-
lation with the corresponding control animals. Tumour-
bearing theophylline-treated animals showed a decrease
in the expression of ubiquitin (42%) and MuRF-1 (53%),
an ubiquitin-dependent ligase that is muscle-specific, in
soleus muscle. Theophylline caused a significant de-
crease in ubiquitin (41%), proteasome subunits C2
(37%), C8 (38%) and E2 (49%) in heart. A tendency to
reduce MuRF-1 mRNA content was also observed with
theophylline treatment, although the differences did not
reach statistical significance.
Concerning other proteolytic systems, tumor burden
also resulted in an increase in the expression of the
calcium-dependent system m- calpain and in the lyso-
somal cathepsin B in heart (Table 2). This proteolytic
mechanism has also been shown to play a role in cancer
cachexia [32]. Theophylline, in the heart, caused a sig-
nificant decrease in m-calpain (45%) mRNA, a compo-
nent the calcium-dependent proteolytic system.
As previously stated, theophylline is able to have anti-
inflammatory effects [13]. Therefore, we examined the
effects of the alkaloid on plasma cytokine levels. The
results, depicted in Figure 4, show that the treatment
significantly decreases TNF-α, (significantly increased
due to the presence of the tumour when compared with
Table 2 Effects of theophylline (50 mg/kg bw) on soleus muscle and heart mRNA content of the different proteolytic
systems in rats bearing the Yoshida AH-130 ascites hepatoma
SOLEUS HEART
Treatment C
(n = 5)
T
(n = 5)
T+ TPH
(n = 6)
ANOVA C
(n = 5)
T
(n = 5)
T + TPH
(n = 6)
ANOVA
A B A B
PROTEOLYTIC SYSTEM
Ubiquitin-dependent
Ubiquitin 100 ± 6 204 ± 15 118± 18 0,000 0,001 100± 5 302 ± 51 177 ± 32 0,001 0,019
Proteasome subunit
C2
100 ± 13 168 ± 10 160± 40 ns ns 100± 3 303 ± 47 191 ± 23 0,000 0,010
Proteasome subunit
C8
100 ± 5 111 ± 8 97± 25 ns ns 100± 3 262 ± 26 164 ± 22 0,000 0,005
E2 100 ± 5 527 ± 129 288± 80 0,004 0,063 100± 5 224 ± 55 114 ± 19 0,013 0,025
MuRF-1 100 ± 3 171 ± 19 80 ± 26 0,025 0,007 100± 3 309 ± 92 177 ± 38 0,015 ns
Atrogin-1 100 ± 8 392 ± 22 362± 71 0,002 ns 100± 3 161 ± 21 152 ± 21 0,039 ns
Calcium-dependent
m-calpain 100 ± 4 117 ± 23 142± 43 ns ns 100± 4 307 ± 58 170 ± 18 0,001 0,009
Lysosomal
Cathepsin-B 100 ± 4 111 ± 8 151± 34 ns ns 100± 2 194 ± 40 111 ± 13 0,010 ns
For further details, see the Material and Methods section. The results are expressed as a percentage of controls (T). All data are mean ± SEM. C = non-tumour-
bearing rats, T = tumour-bearing rats, T + TPH= tumour-bearing rats treated with theophylline. Statistical significance of the results by two-way analysis of variance
(ANOVA) are indicated by: ns (non-significant differences), A (tumour effect), B (treatment effect).
Table 1 Effects of theophylline (50 mg/kg bw) on body
composition in rats bearing the Yoshida AH-130 ascites
hepatoma
Experimental group
C
(n = 6)
T
(n = 10)
T + TPH
(n = 7)
ANOVA
A B
Fat mass (g) 3.2 ± 1.1 −4.3 ± 0.5 −2.3 ± 0.7 0,000 0,045
Lean body mass (g) 23.5 ± 1.5 1.7 ± 1.7 7 ± 3 0,000 ns
Fluids (g) 0.03 ± 0.2 −0.7 ± 0.2 0.04 ± 0.3 0,034 0,025
Results are expressed as the difference between day 0 (tumour inoculation)
and day 7; mean ± SEM. C = non-tumour-bearing rats, T = tumour-bearing rats,
T + TPH= tumour-bearing rats treated with theophylline. Statistical significance
of the results by two-way analysis of variance (ANOVA); ns: non-significant
differences. A (tumour effect); B (treatment effect).
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control animals), while it had no effects on IL-10 (an
anti-inflammatory cytokine). Since TNF-α has been
shown to influence skeletal muscle proteolysis during
cancer cachexia [33], one may speculate that the ef-
fects of theophylline on muscle weight and proteolysis
could be accounted for the changes in this pro-cachectic
cytokine [4].
Based on a clinical study with more than 4000 autopsy
reports, Houten and Reilley [34] suggested that heart
problems are responsible for at least 11% of cancer
deaths. In fact, these data could be underestimated since
a high percentage of deaths are actually attributed to
infections, drug-induced toxicity and alterations in the
osmotic balance, which are mainly due to heart pro-
blems. Therefore, more than 20% of the mortality is due
to alterations in heart function. Indeed, McBride and
collaborators [35] observed that more than 50% of mul-
tiple myeloma patients suffered cardiac failure during
the neoplastic process. Data from our own laboratory
also indicate that tumours implanted in experimental
animals resulted in a decrease of the heart weight [20].
Drott and Lundholm [36] observed an increase in oxy-
gen consumption associated with the heart in an experi-
mental model of cancer. Important ultrastructural
changes characterized by an increase in the ratio of myo-
fibrilles/mitochondria and sarcomeric alterations in a
similar way as observed during cardiac failure were also
reported. Taking this into consideration, and also the
observed effects of theophylline on cardiac mass, we
decided to investigate heart parameters in the ex-
perimental rat model used in our study. The results
presented in Table 3 show that implantation of the
tumour resulted in a posterior wall thickness (PWT)
size decrease. This was associated with a decreased left
ventricle mass (LV). Interestingly, treatment with theo-
phylline increases these parameters, normalizing their
values (Table 3).
Conclusions
From the results presented here, a potential role of theo-
phylline in the treatment of the muscle wasting asso-
ciated with cancer – particularly cardiac muscle – is
postulated. Unfortunately, there is not a perfect thera-
peutic strategy for the treatment of muscle wasting asso-
ciated with cancer. Although a plethora of treatments
have been proposed, the use of a single drug does not
seem to be an ideal approach [37]. It has become in-
creasingly clear that a multifactorial approach is prob-
ably the most suitable treatment. Indeed, combinations
of different nutraceuticals with high protein nutrition
have been highly successful [38]. Theophylline could
perhaps be used in combination with other nutraceuti-
cals, nutrition or drugs in a new approach for the treat-
ment of muscle wasting. Further work is therefore
needed to evaluate the anti-wasting effects of theophyl-
line in combination with other treatments.
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